Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Tarpon Springs, FL, US. The stock last traded at $1.03, down 5.50% on the session, giving a market capitalisation of $16.4M. On trailing twelve-month figures it carries a trailing P/E of -1.32, a net margin of -3575.1%. Its beta of 0.56 implies it has historically moved less than the broad market.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Allarity Therapeutics, Inc. is most often compared with the following Healthcare names: